PER2 under-expression was recently reported for 40 HNSCC primary patient tumour samples [48]; furthermore, leukemic cells over expressing PER2 also led to a reduction in proliferation and clonogenicity [49], which corroborates our miR-193b phenotype (Fig. 2). This evidence concerns the gene PER2 and neoplasm.